New antibody drug tested for patients Who've run out of options

This study is testing whether adding a new antibody drug called HuL001 to standard medications (lenalidomide and dexamethasone) can help control multiple myeloma that has returned or stopped responding to previous treatments. The trial will enroll 21 patients who have already tried several other therapies to check if the combination is safe and effective. Participants will receive HuL001 injections every two weeks while taking the other medications on a set schedule.